Global Alzheimer's Therapeutics Market Analysis 2016 - Forecast to 2022

  • ID: 3845847
  • Report
  • Region: Global
  • 138 pages
  • Hoovers Research
1 of 3
This analysis is one of the most accurate studies performed using the combinational analytical tools. The report contains up to date financial data derived from varied research sources to present unique and reliable analysis. Assessment of major trends with potential impact on the market during the next five years, including a deep dive analysis of market segmentation which comprises of sub markets, regional and country level analysis. The report provides a comprehensive outlook about the market share along with strategic recommendations based on the emerging segments.

This report analyzes the global markets for "Alzheimer’s Therapeutics". The market assessment is performed through standard and the tailored research methodology approach. The market overview offers in depth analysis at the regional and country level, for instance North America (U.S., Canada and Mexico), Europe (Germany, France, Italy, U.K. and Spain), Asia-Pacific (China, Japan, India, Australia, South Korea and Rest of APAC) and Rest of the World (Middle East, Africa and Latin America). Annual estimations and forecasts are provided from the year 2013 to 2022 for each given segment and sub segments. Market data derived from the authenticated and reliable sources is subjected to validation from the industry experts. The report also analyzes the market by discussing market dynamics such as drivers, constraints, opportunities, threats, challenges and other market trends.

Competitive landscaping provides the recent activities performed by the active players in the market. Activities such as product launch, agreements, joint ventures, partnerships, acquisitions and mergers, and other activities.

This report provides:
- Market Sizing estimations and forecasts for a minimum of 6 years of all the given segments, sub segments and the regional markets
- Identifying market dynamics (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Regional and country level market analysis
- Competitive landscaping mapping the key common trends
- Company profiling covering the financials, recent activities and the future strategies
- Supply chain trends mapping the recent advancements
- Strategic recommendations for the new entrants
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Introduction
1.1 Scope of the Report
1.2 Report Description
1.3 Research Methodology
1.4 Research Sources
1.4.1 Secondary Research
1.4.2 Primary Research
1.4.3 Assumptions
1.5 List of Abbreviations

2 Executive Summary

3 Market Analysis
3.1 Market Segmentation
3.2 Market Size Estimation
3.3 Market Drivers
3.4 Market Constraints
3.5 Pipeline Analysis

4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry

5 Alzheimer’s Therapeutics Market by Diagnostics
5.1 Introduction
5.2 Blood Tests
5.3 Brain Imaging

6 Alzheimer’s Therapeutics Market by Product
6.1 Introduction
6.2 Biomarkers
6.3 Acetylcholinesterase Inhibitors
6.3.1 Aricept (donepezil) - Eisai
6.3.2 Cognex (tacrine) - Shionogi
6.3.3 Exelon (rivastigmine) - Novartis
6.3.4 Razadyne (galantamine) - Janssen
6.4 AChEI and NMDA Receptor Antagonists
6.4.1 Namzaric (memantine ER + donepezil), Actavis and Adamas
6.5 NMDA Receptor Antagonists
6.5.1 Namenda/Ebixa/Axura/Abixa (Memantine), Merz/Lundbeck/Forest/Daiichi Sankyo

7 Geographical Segmentation
7.1 North America
7.1.1 US
7.1.2 Canada
7.1.3 Mexico
7.2 Europe
7.2.1 Germany
7.2.2 France
7.2.3 Italy
7.2.4 UK
7.2.5 Spain
7.3 Asia Pacific
7.3.1 Japan
7.3.2 China
7.3.3 India
7.3.4 Australia
7.3.5 New Zealand
7.3.6 Rest of Asia Pacific
7.4 RoW
7.4.1 Latin America
7.4.2 Middle East
7.4.3 Africa
7.4.4 Others

8 Vendor Landscaping
8.1 Agreements, Partnerships, Collaborations and Joint Ventures
8.2 Acquisitions & Mergers
8.3 New Product Launch
8.4 Expansions
8.5 Other Key Strategies

9 Company Profiles
9.1 Actavis
9.1.1 Business Overview
9.1.2 SWOT Analysis
9.1.3 Financial Overview
9.1.4 Strategy
9.1.5 Key Activities
9.2 Acadia Pharmaceuticals, Inc.
9.3 Amarantus Bioscience Holdings
9.4 Axovant Sciences Ltd.
9.5 Bayer Pharmaceuticals
9.6 Biogen
9.7 Biotie Therapies
9.8 Daiichi Sankyo
9.9 Diagenic
9.10 Eisai Co., Ltd.
9.11 Eli Lilly
9.12 F. Hoffmann-La Roche Ltd.
9.13 GE Healthcare
9.14 Genentech
9.15 H. Lundbeck A/S
9.16 Merck & Co. Inc.
9.17 Navidea
9.18 Novartis AG.
9.19 Pfizer, Inc.
9.20 Roche
9.21 Transtech Pharma

10 Appendix
11 Disclaimer

List of Tables
Table 1 Global Alzheimer’s Therapeutics Market Analysis, by Region, 2013-2022 ($MN)
Table 2 Global Alzheimer’s Therapeutics Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 3 Global Blood Tests Market Analysis, by Region, 2013-2022 ($MN)
Table 4 Global Blood Tests Market Analysis, by Product, 2013-2022 ($MN)
Table 5 Global Brain Imaging Market Analysis, by Region, 2013-2022 ($MN)
Table 6 Global Brain Imaging Market Analysis, by Product, 2013-2022 ($MN)
Table 7 Global Alzheimer’s Therapeutics Market Analysis, by Product, 2013-2022 ($MN)
Table 8 Global Biomarkers Market Analysis, by Region, 2013-2022 ($MN)
Table 9 Global Biomarkers Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 10 Global Acetylcholinesterase Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 11 Global Acetylcholinesterase Inhibitors Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 12 Global AChEI and NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 13 Global AChEI and NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 14 Global NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 15 Global NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 16 North America Alzheimer’s Therapeutics Market Analysis, by Region, 2013-2022 ($MN)
Table 17 North America Alzheimer’s Therapeutics Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 18 North America Blood Tests Market Analysis, by Region, 2013-2022 ($MN)
Table 19 North America Blood Tests Market Analysis, by Product, 2013-2022 ($MN)
Table 20 North America Brain Imaging Market Analysis, by Region, 2013-2022 ($MN)
Table 21 North America Brain Imaging Market Analysis, by Product, 2013-2022 ($MN)
Table 22 North America Alzheimer’s Therapeutics Market Analysis, by Product, 2013-2022 ($MN)
Table 23 North America Biomarkers Market Analysis, by Region, 2013-2022 ($MN)
Table 24 North America Biomarkers Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 25 North America Acetylcholinesterase Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 26 North America Acetylcholinesterase Inhibitors Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 27 North America AChEI and NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 28 North America AChEI and NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 29 North America NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 30 North America NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 31 Europe Alzheimer’s Therapeutics Market Analysis, by Region, 2013-2022 ($MN)
Table 32 Europe Alzheimer’s Therapeutics Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 33 Europe Blood Tests Market Analysis, by Region, 2013-2022 ($MN)
Table 34 Europe Blood Tests Market Analysis, by Product, 2013-2022 ($MN)
Table 35 Europe Brain Imaging Market Analysis, by Region, 2013-2022 ($MN)
Table 36 Europe Brain Imaging Market Analysis, by Product, 2013-2022 ($MN)
Table 37 Europe Alzheimer’s Therapeutics Market Analysis, by Product, 2013-2022 ($MN)
Table 38 Europe Biomarkers Market Analysis, by Region, 2013-2022 ($MN)
Table 39 Europe Biomarkers Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 40 Europe Acetylcholinesterase Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 41 Europe Acetylcholinesterase Inhibitors Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 42 Europe AChEI and NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 43 Europe AChEI and NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 44 Europe NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 45 Europe NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 46 Asia Pacific Alzheimer’s Therapeutics Market Analysis, by Region, 2013-2022 ($MN)
Table 47 Asia Pacific Alzheimer’s Therapeutics Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 48 Asia Pacific Blood Tests Market Analysis, by Region, 2013-2022 ($MN)
Table 49 Asia Pacific Blood Tests Market Analysis, by Product, 2013-2022 ($MN)
Table 50 Asia Pacific Brain Imaging Market Analysis, by Region, 2013-2022 ($MN)
Table 51 Asia Pacific Brain Imaging Market Analysis, by Product, 2013-2022 ($MN)
Table 52 Asia Pacific Alzheimer’s Therapeutics Market Analysis, by Product, 2013-2022 ($MN)
Table 53 Asia Pacific Biomarkers Market Analysis, by Region, 2013-2022 ($MN)
Table 54 Asia Pacific Biomarkers Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 55 Asia Pacific Acetylcholinesterase Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 56 Asia Pacific Acetylcholinesterase Inhibitors Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 57 Asia Pacific AChEI and NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 58 Asia Pacific AChEI and NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 59 Asia Pacific NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 60 Asia Pacific NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 61 RoW Alzheimer’s Therapeutics Market Analysis, by Region, 2013-2022 ($MN)
Table 62 RoW Alzheimer’s Therapeutics Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 63 RoW Blood Tests Market Analysis, by Region, 2013-2022 ($MN)
Table 64 RoW Blood Tests Market Analysis, by Product, 2013-2022 ($MN)
Table 65 RoW Brain Imaging Market Analysis, by Region, 2013-2022 ($MN)
Table 66 RoW Brain Imaging Market Analysis, by Product, 2013-2022 ($MN)
Table 67 RoW Alzheimer’s Therapeutics Market Analysis, by Product, 2013-2022 ($MN)
Table 68 RoW Biomarkers Market Analysis, by Region, 2013-2022 ($MN)
Table 69 RoW Biomarkers Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 70 RoW Acetylcholinesterase Inhibitors Market Analysis, by Region, 2013-2022 ($MN)
Table 71 RoW Acetylcholinesterase Inhibitors Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 72 RoW AChEI and NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 73 RoW AChEI and NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Table 74 RoW NMDA Receptor Antagonists Market Analysis, by Region, 2013-2022 ($MN)
Table 75 RoW NMDA Receptor Antagonists Market Analysis, by Diagnostics, 2013-2022 ($MN)
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll